									Known as Ca nalf year/ six m								Amount in	INR Million ex	cept stated otherwise
													dvances or in	vestments m	ade or given b	able only in case the re by the listed entity/sul when such transaction	elated party bsidiary. The	transaction re ese details nee	lates to loans,
	Details of the party entering into the transaction	Details of the counte	erparty			Value of the related			In case monie either party a the trans	s a result of	In case an	y financials ind ake or give loa				Details o	of loans/ inv	estments	
S. No	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/ issuance of debt/ any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
1	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Purchase of goods or services		9	Amount as approved by the Audit Committee.	9	-	-	-		-	-	-	-	-	-	-
2	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Purchase of goods or services		0	Amount as approved by the Audit Committee.	0	-	-	-		-	-	-	-	-	-	-
3	Zydus Lifesciences Limited	Zydus VTEC Limited	Subsidiary Company	Purchase of goods or services		2	Amount as approved by the Audit Committee.	2	-	-	-		-	-	-	-	-	-	-
4	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Purchase of goods or services		101	Amount as approved by the Audit Committee.	101	-	-	-		-	-	-	-	-	-	-
5	Zydus Lifesciences Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Purchase of goods or services		2	Amount as approved by the Audit Committee.	2	-	-	-		-	-	-	-	-	-	-
6	Zydus Lifesciences Limited	Zydus Pharmaceuticals Mexico SA De CV	Subsidiary Company	Purchase of goods or services		0	Amount as approved by the Audit Committee.	0	-	-	-		-	-	-	-	-	-	-
7	Zydus Lifesciences Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Purchase of goods or services		1	Amount as approved by the Audit Committee.	1	-	-	-		-	-	-	-	-	-	-
8	Zydus Lifesciences Limited	Zydus France, SAS	Subsidiary Company	Purchase of goods or services		0	Amount as approved by the Audit Committee.	0	-	-	-		-	-	-	-	-	-	-
9	Zydus Lifesciences Limited	Zydus Healthcare (USA) LLC	Subsidiary Company	Purchase of goods or services		50	Amount as approved by the Audit Committee.	50	-	-	-			-		-	-	-	-
10	Zydus Lifesciences Limited	Zydus Hospira Oncology Private Limited	Joint Ventures	Purchase of goods or services		61	Amount as approved by the Audit Committee.	61	-	-	-		-	-		-	-	-	-

									r Known as Ca half year/ six m								Amount in	INR Million ex	cept stated otherwise
													dvances or inv	vestments m	ade or given b	able only in case the re by the listed entity/sul when such transaction	elated party osidiary. The	transaction re ese details nee	lates to loans,
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related			In case monie either party a the trans	s a result of		y financials ind ake or give loa				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party	Remarks on approval by audit committee	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/ issuance of debt/ any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
11	Zydus Lifesciences Limited	Cadmach Machinery Company Private Limited	Directors and/ or their relatives	Purchase of goods or services		2	Amount as approved by the Audit Committee.	2	-	-	-		-	-	-	-	-	-	-
12	Zydus Lifesciences Limited	Oneiro Chemicals Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		289	Amount as approved by the Audit Committee.	289	-	-	-		-	-	-	-	-	-	-
13	Zydus Lifesciences Limited	Zydus VTEC Limited	Subsidiary Company	Purchase of fixed assets		3	Amount as approved by the Audit Committee.	3	-	-	-		-	-	-	-	-	-	-
14	Zydus Lifesciences Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives			13	Amount as approved by the Audit Committee.	13	-	-	-		-	-	-	-	-	-	-
15	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Purchase of goods or services		0	Amount as approved by the Audit Committee.	o	-	-	-		-	-	-	-	-	-	-
16	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Purchase of goods or services		0	Amount as approved by the Audit Committee.	o	-	-	-		-	-	-	-	-	-	-
17	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Purchase of goods or services		284	Amount as approved by the Audit Committee.	284	-	-	-		-	-	-	-	-	-	-
18	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Purchase of goods or services		4	Amount as approved by the Audit Committee.	4	-	-	-		-	-	-	-	-		-
19	Zydus Lifesciences Limited	Vitely Bio LLP	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		2	Amount as approved by the Audit Committee.	2	-	-	-		-	-	-	-	-	-	-
20	Zydus Lifesciences Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly	Purchase of goods or services		1	Amount as approved by the Audit Committee.	1	-	-	-		-	-	-	-	-	-	-

									Known as Ca half year/ six m								Amount in	INR Million ex	cept stated otherwise
													dvances or in	vestments n	ade or given b	able only in case the r by the listed entity/su when such transaction	elated party bsidiary. The	transaction re se details nee	-
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monie either party a the tran	is a result of	In case an	ny financials ind nake or give loa				Details o	of loans/ inv	estments	-
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/ issuance of debt/ any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
21	Zydus Lifesciences Limited	Cadmach Machinery Company Private Limited	Directors and/ or their relatives	Purchase of goods or services		0	Amount as approved by the Audit Committee.	0	-	-	-		-	-	-	-	-	-	-
22	Zydus Lifesciences Limited	Mukesh M. Patel & Co., Proprietorship Firm	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		4	Amount as approved by the Audit Committee.	4	-	-	-		-	-	-	-	-	-	-
23	Zydus Lifesciences Limited	International Tax & Investment Consultants- Proprietorship Firm	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		3	Amount as approved by the Audit Committee.	3	-	-	-		-	-	-	-	-	-	-
24	Zydus Lifesciences Limited	Sahyadri Hospitals Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		1	Amount as approved by the Audit Committee.	1	-	-	-		-	-	-	-	-	-	-
25	Zydus Lifesciences Limited	TUV India Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		0	Amount as approved by the Audit Committee.	0	-	-	-		-	-	-	-	-	-	-
26	Zydus Lifesciences Limited	Apollo Healthco Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		1	Amount as approved by the Audit Committee.	1	-	-	-		-	-	-	-	-	-	-
27	Zydus Lifesciences Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		41	Amount as approved by the Audit Committee.	41	-	-	-		-	-	-	-	-	-	-
28	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses paid	336	Amount as approved by the Audit Committee.	336	-	-	-		-	-	-	-	-	-	-
29	Zydus Lifesciences Limited	Zydus Healthcare (USA) LLC	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses paid	18	Amount as approved by the Audit Committee.	18	-	-	-		-	-	-	-	-	-	-
30	Zydus Lifesciences Limited	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses paid	3	Amount as approved by the Audit Committee.	3	-	-	-		-	-	-	-	-	-	-

									Known as Ca nalf year/ six m								Amount in	INR Million exe	cept stated otherwise
													dvances or inv	estments m	ade or given b	ble only in case the re	elated party bsidiary. The	transaction re ese details nee	
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related			In case monie either party a the trans	s a result of	In case an	y financials ind nake or give loa				Details o	of loans/ inv	estments	
S. No	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/ issuance of debt/ any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
31	Zydus Lifesciences Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses paid	11	Amount as approved by the Audit Committee.	11	-	-	-		-	-	-	-	-	-	-
32	Zydus Lifesciences Limited	Zydus Pharmaceuticals Mexico SA De CV	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses paid	6	Amount as approved by the Audit Committee.	6	-	-	-		-	-	-	-	-	-	-
33	Zydus Lifesciences Limited	Zydus France, SAS	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses paid	106	Amount as approved by the Audit Committee.	106	-	-	-		-	-	-	-	-	-	-
34	Zydus Lifesciences Limited	Laboratorios Combix S.L.	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses paid	43	Amount as approved by the Audit Committee.	43	-	-	-		-	-	-	-	-	-	-
35	Zydus Lifesciences Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses paid	17	Amount as approved by the Audit Committee.	17	-	-	-		-	-	-	-	-	-	-
36	Zydus Lifesciences Limited	Zydus Hospira Oncology Private Limited	Joint Ventures	Any other transaction	Reimburseme nt of Expenses paid	1	Amount as approved by the Audit Committee.	1	-	-	-		-	-	-	-	-	-	-
37	Zydus Lifesciences Limited	Bayer Zydus Pharma Private Limited	Joint Ventures	Any other transaction	Reimburseme nt of Expenses paid	0	Amount as approved by the Audit Committee.	0	-	-	-		-	-	-	-	-	-	-
38	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Sale of goods or services		0	Amount as approved by the Audit Committee.	0	-	-	-		-	-	-	-	-	-	-
39	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Sale of goods or services		256	Amount as approved by the Audit Committee.	256	-	-	-			-	-	-	-	-	-
40	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Sale of goods or services		341	Amount as approved by the Audit Committee.	341	-	-	-		-	-	-	-	-	-	-

									Known as Ca nalf year/ six m								Amount in	INR Million ex	cept stated otherwise
													dvances or in	vestments m	ade or given b	able only in case the r	elated party bsidiary. The	transaction re ese details nee	
	Details of the party entering into the transaction	Details of the counte	erparty			Value of the related			In case monie either party a the trans	is a result of	In case an	ny financials ind nake or give loa				Details o	of loans/ inv	estments	
S. No	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/ issuance of debt/ any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
41	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Sale of goods or services		30,470	Amount as approved by the Audit Committee.	30,470	-	-	-		-	-	-	-	-	-	-
42	Zydus Lifesciences Limited	Viona Pharmaceuticals INC	Subsidiary Company	Sale of goods or services		1,048	Amount as approved by the Audit Committee.	1,048	-	-	-		-	-	-	-	-	-	-
43	Zydus Lifesciences Limited	Zydus Healthcare Philippines Inc.	Subsidiary Company	Sale of goods or services		253	Amount as approved by the Audit Committee.	253	-	-	-		-	-	-	-	-	-	-
44	Zydus Lifesciences Limited	Alidac Healthcare (Myanmar) Limited	Subsidiary Company	Sale of goods or services		130	Amount as approved by the Audit Committee.	130	-	-	-		-	-	-	-	-	-	-
45	Zydus Lifesciences Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Sale of goods or services		347	Amount as approved by the Audit Committee.	347	-	-	-		-	-	-	-	-	-	-
46	Zydus Lifesciences Limited	Zydus Pharmaceuticals Mexico SA De CV	Subsidiary Company	Sale of goods or services		527	Amount as approved by the Audit Committee.	527	-	-	-		-	-	-	-	-	-	-
47	Zydus Lifesciences Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Sale of goods or services		315	Amount as approved by the Audit Committee.	315	-	-	-		-	-	-	-	-	-	-
48	Zydus Lifesciences Limited	Zydus France, SAS	Subsidiary Company	Sale of goods or services		282	Amount as approved by the Audit Committee.	282	-	-	-		-	-	-	-	-	-	-
49	Zydus Lifesciences Limited	Laboratorios Combix S.L.	Subsidiary Company	Sale of goods or services		166	Amount as approved by the Audit Committee.	166	-	-	-		-	-	-	-	-	-	-
50	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Sale of goods or services		1,255	Amount as approved by the Audit Committee.	1,255	-	-	-		-	-	-	-	-	-	-

									r Known as Ca half year/ six m								Amount in	INR Million ex	cept stated otherwise
													dvances or in	vestments m	ade or given b	able only in case the re by the listed entity/sub when such transaction	elated party osidiary. The	transaction re ese details nee	elates to loans,
	Details of the party entering into the transaction	Details of the counte	erparty			Value of the related			In case monie either party a the trans	s a result of		y financials ind ake or give loa				Details o	of loans/ inv	restments	
S. No	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/ issuance of debt/ any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
51	Zydus Lifesciences Limited	Zydus Takeda Healthcare Private Limited	Joint Ventures	Sale of goods or services		154	Amount as approved by the Audit Committee.	154	-	-	-		-	-	-	-	-	-	-
52	Zydus Lifesciences Limited	Bayer Zydus Pharma Private Limited	Joint Ventures	Sale of goods or services		8	Amount as approved by the Audit Committee.	8	-	-	-		-	-	-	-	-	-	-
53	Zydus Lifesciences Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Sale of goods or services		6	Amount as approved by the Audit Committee.	6	-	-	-		-	-	-	-	-	-	-
54	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limitec	Subsidiary Company	Sale of fixed assets		3	Amount as approved by the Audit Committee.	3	-	-	-		-	-	-	-	-	-	-
55	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Sale of fixed assets		1	Amount as approved by the Audit Committee.	1	-	-	-		-	-	-	-	-	-	-
56	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Sale of fixed assets		0	Amount as approved by the Audit Committee.	o	-	-	-		-	-	-	-	-	-	-
57	Zydus Lifesciences Limited	Zydus Wellness Limited	Subsidiary Company	Sale of goods or services		4	Amount as approved by the Audit Committee.	4	-	-	-		-	-	-	-	-	-	-
58	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Sale of goods or services		8	Amount as approved by the Audit Committee.	8	-	-	-		-	-	-	-	-	-	-
59	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Sale of goods or services		3	Amount as approved by the Audit Committee.	3	-	-	-		-	-	-	-	-	-	-
60	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Sale of goods or services		4	Amount as approved by the Audit Committee.	4	-	-	-		-	-	-	-	-	-	-

									Known as Ca half year/ six m								Amount in	INR Million ex	cept stated otherwise
													dvances or in	vestments n	nade or given l	able only in case the r by the listed entity/su vhen such transaction	elated party bsidiary. Th	transaction rese details nee	
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related			In case monie either party a the trans	s a result of		ny financials ind nake or give loa				Details	of loans/ inv	restments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/ issuance of debt/ any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
61	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Sale of goods or services		1	Amount as approved by the Audit Committee.	1	-	-	-		-	-	-	-	-	-	-
62	Zydus Lifesciences Limited	Zydus VTEC Limited	Subsidiary Company	Sale of goods or services		6	Amount as approved by the Audit Committee.	6	-	-	-		-	-	-	-	-	-	-
63	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Sale of goods or services		257	Amount as approved by the Audit Committee.	257	-	-	-		-	-	-	-	-	-	-
64	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Sale of goods or services		79	Amount as approved by the Audit Committee.	79	-	-	-		-	-	-	-	-	-	-
65	Zydus Lifesciences Limited	Sentynl Therapeutics Inc.	Subsidiary Company	Sale of goods or services		5	Amount as approved by the Audit Committee.	5	-	-	-		-	-	-	-	-	-	-
66	Zydus Lifesciences Limited	Viona Pharmaceuticals INC	Subsidiary Company	Sale of goods or services		3	Amount as approved by the Audit Committee.	3	-	-	-		-	-	-	-	-	-	-
67	Zydus Lifesciences Limited	Zydus Therapeutics INC	Subsidiary Company	Sale of goods or services		22	Amount as approved by the Audit Committee.	22	-	-	-		-	-	-	-	-	-	-
68	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Sale of goods or services		154	Amount as approved by the Audit Committee.	154	-	-	-		-	-	-	-	-	-	-
69	Zydus Lifesciences Limited	Zydus Hospira Oncology Private Limited	Joint Ventures	Sale of goods or services		0	Amount as approved by the Audit Committee.	0	-	-	-		-	-	-	-	-	-	-
70	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	42	Amount as approved by the Audit Committee.	42	-	-	-		-	-	-	-	-	-	-

									Known as Ca half year/ six m								Amount in	INR Million ex	cept stated otherwise
													dvances or inv	estments m	ade or given b	able only in case the re by the listed entity/sub when such transaction	elated party osidiary. The	transaction re ese details nee	elates to loans,
	Details of the party entering into the transaction	Details of the counte	erparty			Value of the related			In case monie either party a the trans	s a result of		y financials ind ake or give loa				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/ issuance of debt/ any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
71	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	102	Amount as approved by the Audit Committee.	102	-	-	-		-	-	-	-	-	-	-
72	Zydus Lifesciences Limited	Zydus Wellness Limited	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	0	Amount as approved by the Audit Committee.	0	-	-	-		-	-	-	-	-	-	-
73	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	1	Amount as approved by the Audit Committee.	1	-	-	-		-	-	-	-	-	-	-
74	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	7	Amount as approved by the Audit Committee.	7	-	-	-		-	-	-	-	-	-	-
75	Zydus Lifesciences Limited	Mr. Pankaj R. Patel	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	1	-	-	-		-	-	-	-	-	-	-
76	Zydus Lifesciences Limited	Mr. Mukesh M. Patel	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	1	-	-	-		-	-	-	-	-	-	-
77	Zydus Lifesciences Limited	Mr. Nitin Raojibhai Desai	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
78	Zydus Lifesciences Limited	Mr. Apurva S. Diwanji	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	1	-	-	-		-	-	-	-	-	-	-
79	Zydus Lifesciences Limited	Ms. Dharmishta N. Raval	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	1	-	-	-		-	-	-	-	-	-	-

									Known as Ca half year/ six m								Amount in	INR Million ex	ccept stated otherwise
													dvances or inv	estments m	ade or given b	able only in case the r by the listed entity/su vhen such transaction	bsidiary. The	ese details nee	elates to loans, ed to be disclosed only
	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of		ny financials ind nake or give loa				Details (	of loans/ inv	estments	-
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/ issuance of debt/ any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
80	Zydus Lifesciences Limited	Mr. Bhadresh K. Shah	Key Managerial Personnel		Director Sitting Fees and Commission to non executive <u>directors</u>	-	N.A.	1	-	-	-		-	-	-	-	-	-	-
81	Zydus Lifesciences Limited	Mr. Akhil Monappa	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive <u>directors</u>	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
82	Zydus Lifesciences Limited	Mrs. Upasana Konidela	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive <u>directors</u>	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
83	Zydus Lifesciences Limited	Dr. Sharvil P. Patel	Key Managerial Personnel	Remuneration		-	N.A.	123	-	-	-		-	-	-	-	-	-	-
84	Zydus Lifesciences Limited	Mr. Ganesh N. Nayak	Key Managerial Personnel	Remuneration		-	N.A.	61	-	-	-		-	-	-	-	-	-	-
85	Zydus Lifesciences Limited	Mr. Nitin D. Parekh	Key Managerial Personnel	Remuneration		-	N.A.	42	-	-	-		-	-	-	-	-	-	-
86	Zydus Lifesciences Limited	Mr. Dhaval N. Soni	Key Managerial Personnel	Remuneration		-	N.A.	2	-	-	-		-	-	-	-	-	-	-
87	Zydus Lifesciences Limited	Dialforhealth Unity Limited	Subsidiary Company	Interest received		-	N.A.	0	-	-	-		-	-	-	-	-	-	-
88	Zydus Lifesciences Limited	Zydus International Private Limited	Subsidiary Company	Interest received		-	N.A.	353	-	-	-	†	-	-	-	-	-	-	
89	Zydus Lifesciences Limited		Subsidiary Company	Interest received		-	N.A.	396	-	-	-	<u> </u>	-		-	-	-	-	
90	Zydus Lifesciences Limited	Sentynl Therapeutics Inc.	Subsidiary Company	Interest received		-	N.A.	37	-		-	†	-		-	-	-	-	
91	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Interest received		-	N.A.	388	-		-	+	-		-	-	-	-	
92	Zydus Lifesciences Limited	Bayer Zydus Pharma Private Limited		Interest received		-	N.A.	2	-	-	-	†	-	-	-	-	-	-	
93	Zydus Lifesciences Limited		Subsidiary Company	Interest paid		-	N.A.	39	-	-	-		-	-	-	-	-	-	
94	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Interest paid		-	N.A.	892	-	-	-		-	-	-	-	-	-	-
95	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Interest paid		-	N.A.	745	-	-	-		-	-	-	-	-	-	-
96	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Loan		-	N.A.	824	-	-	-		-	-	Loan	6 Month SOFR + 80 bps	5 Year	Unsecured	Business Purpose
97	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Investment		-	N.A.	5,700	-	5,700	-	T	-	-	Investment	N.A	N.A	Unsecured	Business Purpose
98	Zydus Lifesciences Limited	Zydus VTEC Limited	Subsidiary Company	Investment		-	N.A.	2,950	-	2,950	-	T	-	-	Investment	N.A	N.A	Unsecured	Business Purpose
99	Zydus Lifesciences Limited	Zynext Ventures Pte. Ltd.	Subsidiary Company	Investment		-	N.A.	21	-	21	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose
100	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Investment		-	N.A.	198		198	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose

									Known as Ca half year/ six m								Amount in	INR Million ex	cept stated otherwise
													dvances or in	vestments n	nade or given l	able only in case the r by the listed entity/su when such transaction	elated party bsidiary. The	transaction re ese details nee	-
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related			In case monie either party a the tran	is a result of		ny financials ind nake or give loa				Details (	of loans/ inv	estments	
S. No	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	as	Remarks on approval by audit committee	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/ issuance of debt/ any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
101	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Loan		-	N.A.	2,010	-	-	-		-	-	-	-	-	-	-
102	Zydus Lifesciences Limited	Cadila Healthcare Ltd. Managerial Cadre EPF	Post Employment Benefit Plans	Any other transaction	Contributions during the year (includes Employee's share and contribution)		N.A.	251	-	-	-		-	-	-	-	-	-	-
103	Zydus Lifesciences Limited	Cadila Healthcare Limited Employees Group Gratuity Scheme	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]		N.A.	73	-	-	-		-	-	-	-	-	-	-
104	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.	-	23,467	22,324	-		-			-	-	-	
105	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.	-	14,549	25,702	-		-	-	-	-	-	-	-
106	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.	-	823	1,035	-		-	-	-	-	-	-	-
107	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	42	-	-		-	-	-	-	-	-	-
108	Zydus Lifesciences Limited	Zydus VTEC Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	0	0	-		-	-	-	-	-	-	-
109	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	282	149	-		-	-	-	-	-	-	-
110	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	374	625	-		-	-	-	-	-	-	-
111	Zydus Lifesciences Limited	Zydus Healthcare (USA) LLC	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	39	46	-		-	-	-	-	-	-	-
112	Zydus Lifesciences Limited	Nesher Pharmaceuticals (USA) LLC	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	2	2	-		-	-	-	-	-	-	-
113	Zydus Lifesciences Limited	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	67	70	-		-	-	-	-	-	-	-
114	Zydus Lifesciences Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	164	167	-		-	-	-	-	-	-	-

									r Known as Ca half year/ six m								Amount in	INR Million ex	cept stated otherwise
													dvances or inv	estments m	ade or given b	able only in case the re by the listed entity/sub when such transaction	elated party osidiary. The	transaction re se details nee	lates to loans,
	Details of the party entering into the transaction	Details of the counte	erparty			Value of the related			In case monie either party a the trans	s a result of		y financials ind ake or give loa				Details o	f loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/ issuance of debt/ any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
115	Zydus Lifesciences Limited	Zydus Pharmaceuticals Mexico SA De CV	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	31	37	-		-	-	-	-	-	-	-
116	Zydus Lifesciences Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	29	47	-		-	-	-	-	-	-	-
117	Zydus Lifesciences Limited	Zydus France, SAS	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	162	111	-		-	-	-	-	-	-	-
118	Zydus Lifesciences Limited	Zydus Lanka (Private) Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	1	1	-		-	-	-	-	-	-	-
119	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	3	2	-		-	-	-	-	-	-	-
120	Zydus Lifesciences Limited	Zydus Hospira Oncology Private Limited	Joint Ventures	Any other transaction	Outstanding Payables - Other than <u>Ioans</u>	-	N.A.	-	48	22	-		-	-	-	-	-	-	-
121	Zydus Lifesciences Limited	Vitely Bio LLP	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	2	-	-		-	-	-	-	-	-	-
122	Zydus Lifesciences Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	0	0	-		-	-	-	-	-	-	-
123	Zydus Lifesciences Limited	Cadmach Machinery Company Private Limited	Enterprises significantly	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	0	0	-		-	-	-	-	-	-	-
124	Zydus Lifesciences Limited	Cadila Laboratories Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	22	22	-		-	-	-	-	-	-	-
125	Zydus Lifesciences Limited	Oneiro Chemicals Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	88	98	-		-	-	-	-	-	-	-
126	Zydus Lifesciences Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	12	4	-		-	-	-	-	-	-	-

									Known as Ca half year/ six m										
									,,			,					Amount in	INR Million ex	cept stated otherwise
													dvances or inv	estments m	ade or given b	able only in case the re by the listed entity/sub when such transaction	osidiary. The	ese details nee	
	Details of the party entering into the transaction	Details of the counte	erparty			Value of the related			In case monie either party a the trans	s a result of		ny financials ind nake or give loa				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/ issuance of debt/ any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
127	Zydus Lifesciences Limited	Aleta Hospitals LLP [Formerly known as Zydus Hospitals (Vadodara) LLP]	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	0	0	-		-	-	-	-	-	-	-
128	Zydus Lifesciences Limited	Dr. Sharvil P. Patel	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	91	-	-		-	-	-	-	-	-	-
129	Zydus Lifesciences Limited	Mr. Ganesh N. Nayak	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	36	-	-		-	-	-	-	-	-	-
130	Zydus Lifesciences Limited	Mr. Nitin D. Parekh	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	2	-	-		-	-	-	-	-	-	-
131	Zydus Lifesciences Limited	Mr. Dhaval N. Soni	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	0	-	-		-	-	-	-	-	-	-
132	Zydus Lifesciences Limited	Mr. Mukesh M. Patel	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	3	-	-		-	-	-	-	-	-	-
133	Zydus Lifesciences Limited	Mr. Apurva S. Diwanji	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	3	-	-		-	-	-	-	-	-	-
134	Zydus Lifesciences Limited	Mr. Nitin Raojibhai Desai	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	3	-	-		-	-	-	-	-	-	-
135	Zydus Lifesciences Limited	Ms. Dharmishta N. Raval	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	3	-	-		-	-	-	-	-	-	-
136	Zydus Lifesciences Limited	Mr. Bhadresh K. Shah	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	3	-	-		-	-	-	-	-	-	-
137	Zydus Lifesciences Limited	Mr. Akhil Monappa	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	1	-	-	 	-	-	-	-	-	-	-
138	Zydus Lifesciences Limited	Mrs. Upasana Konidela	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	1	-	-	 	-	-	-	-	-	-	-
139	Zydus Lifesciences Limited	Dialforhealth Unity Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	2	2	-		-	-		-	-	-	-
140	Zydus Lifesciences Limited	Zydus International Private Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	12,096	12,575	-		-	-	-	-	-	-	-
141	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	13,555	13,698	-		-	-	-	-	-	-	-

									r Known as Ca half year/ six m								Amount in	INR Million ex	cept stated otherwise
													dvances or in	vestments n	nade or given l	able only in case the r by the listed entity/su vhen such transaction	bsidiary. The	ese details nee	elates to loans, ed to be disclosed only
	Details of the party entering into the transaction	Details of the counte	erparty			Value of the related			In case monie either party a the tran	as a result of		ny financials ind nake or give loa				Details	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/ issuance of debt/ any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
142	Zydus Lifesciences Limited	Sentynl Therapeutics Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	1,257	1,282	-		-	-	-	-	-	-	-
143	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	12,918	13,989	-		-	-	-	-	-	-	-
144	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	158	237	-		-	-	-	-	-	-	-
145	Zydus Lifesciences Limited	Zydus Wellness Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	11	3	-	+	-	-	-	-	-	-	-
146	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	37	45	-		-	-	-	-	-	-	
147	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	15	5	-		-	-	-	-	-	-	
148	3 Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	49	30	-		-	-	-	-	-	-	-
149	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	194	286	-		-	-	-	-	-	-	-
150	) Zydus Lifesciences Limited	Zydus VTEC Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	2	4	-		-	-	-	-	-	-	-
151	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	23,877	19,594	-		-	-	-	-	-	-	-
152	Zydus Lifesciences Limited	Sentynl Therapeutics Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	12	4	-		-	-	-	-	-	-	-
153	Zydus Lifesciences Limited	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	684	1,025	-		-	-	-	-	-	-	-
154	Zydus Lifesciences Limited	Zydus Therapeutics INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	21	21	-		-	-	-	-	-	-	-
155	Zydus Lifesciences Limited	Zydus Healthcare Philippines Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	257	237	-		-	-	-	-	-	-	-
156	Zydus Lifesciences Limited	Alidac Healthcare (Myanmar) Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	188	318	-	+	-	-		-	-	-	-

									Known as Ca half year/ six m								Amount in	INR Million ex	cept stated otherwise
													dvances or inv	vestments m	ade or given b	able only in case the re by the listed entity/sub when such transaction	elated party osidiary. The	transaction re ese details nee	lates to loans,
	Details of the party entering into the transaction	Details of the counte	erparty			Value of the related		Value of	In case monie either party a the trans	s a result of		y financials ind ake or give loa				Details o	f loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/ issuance of debt/ any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
157	Zydus Lifesciences Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	410	534	-		-	-	-	-	-	-	-
158	Zydus Lifesciences Limited	Zydus Pharmaceuticals Mexico SA De CV	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	718	772	-		-	-	-	-	-	-	-
159	Zydus Lifesciences Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	1,245	944	-		-	-	-	-	-	-	-
160	Zydus Lifesciences Limited	Zydus France, SAS	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	397	485	-		-	-	-	-	-	-	-
161	Zydus Lifesciences Limited	Etna Biotech S.R.L.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	76	76	-		-	-	-	-	-	-	-
162	Zydus Lifesciences Limited	Laboratorios Combix S.L.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	153	177	-		-	-	-	-	-	-	-
163	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	1,159	1,522	-		-	-	-	-	-	-	-
164	Zydus Lifesciences Limited	Bayer Zydus Pharma Private Limited	Joint Ventures	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	0	0	-		-	-	-	-	-	-	-
165	Zydus Lifesciences Limited	Zydus Takeda Healthcare Private Limited		Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	97	112	-		-	-	-	-	-	-	-
166	Zydus Lifesciences Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	2	6	-		-	-	-	-	-	-	-
167	Zydus Lifesciences Limited	Cadmach Machinery Company Private Limited	Enterprises significantly	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	4	-	-		_	-	-	-	-	-	-
168	Zydus Healthcare Limited	Oneiro Chemicals Private Limited	Enterprises significantly	Purchase of goods or services		1	Amount as approved by the Audit Committee.	1	-	-	-		-	-	-	-	-	-	-
169	Zydus Healthcare Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Purchase of goods or services		0	Amount as approved by the Audit Committee.	0	-	-	-		-	-	-	-	-	-	-

									Known as Ca half year/ six m								Amount in	INR Million ex	cept stated otherwise
													dvances or in	vestments m	ade or given b	able only in case the re	elated party osidiary. The	transaction re ese details nee	
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related			In case monie either party a the trans	s a result of		y financials ind ake or give loa				Details o	f loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/ issuance of debt/ any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
170	Zydus Healthcare Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		0	Amount as approved by the Audit Committee.	0	-	-	-		-	-	-	-	-	-	-
171	Zydus Healthcare Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Purchase of goods or services		0	Amount as approved by the Audit Committee.	0	-	-	-		-	-	-	-	-	-	-
172	Zydus Healthcare Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		0	Amount as approved by the Audit Committee.	0	-	-	-		-	-	-	-	-	-	-
173	Zydus Healthcare Limited	Mukesh M. Patel & Co., Proprietorship Firm	Enterprises significantly	Purchase of goods or services		1	Amount as approved by the Audit Committee.	1	-	-	-		-	-	-	-	-	-	-
174	Zydus Healthcare Limited	German Remedies Pharma Private Limited	Subsidiary Company	Sale of goods or services		69	Amount as approved by the Audit Committee.	69	-	-	-		-	-	-	-	-	-	-
175	Zydus Healthcare Limited	Zydus Wellness Products Limited	Subsidiary Company	Sale of goods or services		1	Amount as approved by the Audit Committee.	1	-	-	-		-	-	-	-	-	-	-
176	Zydus Healthcare Limited	Bayer Zydus Pharma Private Limited	Joint Ventures	Sale of goods or services		30	Amount as approved by the Audit Committee.	30	-	-	-		-	-	-	-	-	-	-
177	Zydus Healthcare Limited	Zydus Hospitals and Healthcare Research Private Limited	Directors and/ or their relatives	Sale of goods or services		13	Amount as approved by the Audit Committee.	13	-	-	-		-	-	-	-	-	-	-
178	Zydus Healthcare Limited	Ramanbhai Foundation	Enterprises significantly influenced by Directors and/ or their relatives	Sale of goods or services		1	Amount as approved by the Audit Committee.	1	-	-	-		-	-	-	-	-	-	-
179	Zydus Healthcare Limited	Zydus Wellness Products Limited	Subsidiary Company	Sale of fixed assets		1	Amount as approved by the Audit Committee.	1	-	-	-		-	-		-	-	-	-

									Known as Ca half year/ six m								Amount in	INR Million ex	cept stated otherwise
													dvances or inv	vestments m	ade or given b	able only in case the ro by the listed entity/sul when such transaction	elated party osidiary. The	transaction re ese details nee	
	Details of the party entering into the transaction	Details of the counte	erparty			Value of the related			In case monie either party a the trans	s a result of		y financials ind ake or give loa				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/ issuance of debt/ any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
180	Zydus Healthcare Limited	Zydus Wellness Products Limited	Subsidiary Company	Sale of goods or services		7	Amount as approved by the Audit Committee.	7	-	-	-		-	-	-	-	-	-	-
181	Zydus Healthcare Limited	Mr. Harish Sadana	Key Managerial Personnel	Remuneration		-	N.A.	41	-	-	-		-	-	-	-	-	-	-
182	Zydus Healthcare Limited	Mr. Arvind Bothra	Key Managerial Personnel	Remuneration		-	N.A.	12	-	-	-		-	-	-	-	-	-	-
183	Zydus Healthcare Limited	Mr. Venkata Chalapathi Rao Neti	Key Managerial Personnel Key	Remuneration		-	N.A.	3	-	-	-		-	-	-	-	-		-
184	Zydus Healthcare Limited	Mr. Sanjay Kumar Gupta	Managerial Personnel	Remuneration	Director	-	N.A.	2	-	-	-		-	-	-	-	-	-	-
185	Zydus Healthcare Limited	Dr. Sharvil P. Patel	Key Managerial Personnel	Any other transaction	Sitting Fees and Commission to non executive directors	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
186	Zydus Healthcare Limited	Ms. Dharmishta N. Raval	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
187	Zydus Healthcare Limited	Mr. Nitin D. Parekh	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
188	Zydus Healthcare Limited	Mr. Deevyesh J. Radia	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
189	Zydus Healthcare Limited	Dr. Bhavna Doshi	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
190	Zydus Healthcare Limited	Zydus Wellness Products Limited	Subsidiary Company	Interest received		-	N.A.	83	-	-	-		-	-		-	-	-	
191	Zydus Healthcare Limited	Zydus Pharmaceuticals Limited	Subsidiary Company Subsidiary	Interest received		-	N.A.	122	-	-	-		-		-	-	-	-	
192	Zydus Healthcare Limited	Zydus VTEC Limited	Company	Interest received	<u> </u>	-	N.A.	62	-	-	-		-	-	-	-	-	-	-

									Known as Ca aalf year/ six mo								Amount in	INR Million ex	cept stated otherwise
													dvances or inv	estments n	nade or given b	able only in case the re by the listed entity/sul when such transaction	elated party bsidiary. The	transaction re se details nee	lates to loans,
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related			In case monies either party as the trans	s a result of		y financials ind ake or give loa				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/ issuance of debt/ any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
193	Zydus Healthcare Limited	Zydus Lifesciences Limited	Parent Company	Loan		-	N.A.	870	-	-	-		-	-	Loan	TBILL+150 bps	3 Year	Unsecured	Business Purpose
194	Zydus Healthcare Limited	Zydus Lifesciences Limited	Parent Company	Loan		-	N.A.	7,000	-	-	-		-	-	Loan	1 Month TBILL+50 bps	3 Year	Unsecured	Business Purpose
195	Zydus Healthcare Limited	Zydus Lifesciences Limited	Parent Company	Loan		-	N.A.	3,255	-	-	-		-	-	Loan	1 Month TBILL+60	3 Year	Unsecured	Business Purpose
196	Zydus Healthcare Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Loan		-	N.A.	729	-	-	-		-	-	Loan	1 year GSEC +50 bps	5 Year	Unsecured	Business Purpose
197	Zydus Healthcare Limited	Zydus VTEC Limited	Subsidiary Company	Loan		-	N.A.	83		-	-		-	-	Loan	1 year GSEC +50 bps	3 Year	Unsecured	Business Purpose
198	Zydus Healthcare Limited	Zydus Lifesciences Limited	Parent Company	Loan		-	N.A.	222	-	-	-		-		-	-	-	-	
199	Zydus Healthcare Limited	Zydus VTEC Limited	Subsidiary Company	Loan		-	N.A.	2,868	-	-	-		-	-	-	-	-	-	-
200	Zydus Healthcare Limited	Zydus Wellness Products Limited	Subsidiary Company	Loan		-	N.A.	945	-	-	-	<b></b>	-	-	-	-	-	-	
201	Zydus Healthcare Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Loan		-	N.A.	5,567		-	-		-	-	-	-	-	-	
202	Zydus Healthcare Limited	Recon Pharmaceuticals and Investments	Subsidiary Company	Any other transaction	Share of profit Received	-	N.A.	0	-	-	-		-	-	-	-		-	
203	Zydus Healthcare Limited	Zydus Healthcare Limited Employees Group Gratuity Scheme	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.	19	-	-	-		-	-	-	-	-	-	-
204	Zydus Healthcare Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	0	0	-		-	-	-	-	-	-	-
205	Zydus Healthcare Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	-	0	-		-	-	-	-	-	-	-
206	Zydus Healthcare Limited	Oneiro Chemicals Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	-	1	-		-	-	-	-	-	-	-
207	Zydus Healthcare Limited	Ms. Dharmishta N. Raval	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	0	-	-		-	-	-	-	-	-	-
208	Zydus Healthcare Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans		N.A.	-	2,955	2,047	-			-		-	-	-	
209	Zydus Healthcare Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans		N.A.	-	5,028	33	-			-		-	-	-	-
210	Zydus Healthcare Limited	Zydus VTEC Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	2,828	-	-		-	-	-	-	-	-	-

									r Known as Ca half year/ six m								Amount in	INR Million ex	cept stated otherwise
													dvances or in	vestments m	ade or given l	able only in case the r by the listed entity/su when such transaction	elated party bsidiary. The	transaction re ese details nee	
	Details of the party entering into the transaction	Details of the counte	erparty			Value of the related			In case monie either party a the tran	as a result of		ny financials inc nake or give loa				Details	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/ issuance of debt/ any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
211	Zydus Healthcare Limited	Bayer Zydus Pharma Private Limited	Joint Ventures	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	12	7	-		-	-	-	-	-	-	-
212	Zydus Healthcare Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	-	2	-		-	-	-	-	-	-	-
213	Zydus Healthcare Limited	German Remedies Pharma Private Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	-	16	-		-	-	-	-	-	-	-
214	Zydus Healthcare Limited	Ramanbhai Foundation	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	-	0	-		-	-	-	-	-	-	-
215	Zydus Healthcare Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	4	5	-		-	-	-	-	-	-	-
216	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Purchase of goods or services		71	Amount as approved by the Audit Committee.	71	-	-	-		-	-	-	-	-	-	-
217	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Purchase of fixed assets		0	Amount as approved by the Audit Committee.	0	-	-	-		-	-	-	-	-	-	-
218	Zydus Wellness Limited	Mukesh M. Patel & Co., Proprietorship Firm	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		1	Amount as approved by the Audit Committee.	1	-	-	-		-	-	-	-	-	-	-
219	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses paid	13	Amount as approved by the Audit Committee.	13	-	-	-		-	-	-	-	-	-	-
220	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Sale of goods or services		1,004	Amount as approved by the Audit Committee.	1,004	-	-	-		-	-	-	-	-	-	-
221	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Sale of goods or services		8	Amount as approved by the Audit Committee.	8	-	-			-	-	-	-	-	-	-

									Known as Ca nalf year/ six m								Amount in	INR Million ex	cept stated otherwise
													dvances or in	estments m	ade or given b	ble only in case the re	elated party osidiary. The	transaction re ese details nee	
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of		ny financials ind nake or give loa				Details o	f loans/ inv	estments	
S. No	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/ issuance of debt/ any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
22	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Sale of fixed assets		11	Amount as approved by the Audit Committee.	11	-	-	-		-	-	-	-	-	-	-
22:	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Sale of goods or services		161	Amount as approved by the Audit Committee.	161	-	-	-		-	-	-	-	-	-	-
224	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	4	Amount as approved by the Audit Committee.	4	-	-	-		-	-	-	-	-	-	-
22!	Zydus Wellness Limited	Dr. Sharvil P. Patel	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
220	Zydus Wellness Limited	Mr. Ganesh N. Nayak	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	1	-	-	-		-	-	-	-	-	-	-
22	Zydus Wellness Limited	Mr. Akhil Monappa	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
228	Zydus Wellness Limited	Mr. Kulin Sanjay Lalbhai	Key Managerial Personnel	Any other transaction	Director Sitting Fees and		N.A.	1	-	-	-	+	-			-	-	-	
229	Zydus Wellness Limited	Mr. Srivishnu Raju Nandayala	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	1	-	-	-		-	-	-	-	-	-	-
230	Zydus Wellness Limited	Mr. Savyasachi S. Sengupta	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	1	-	-	-		-	-	-	-	-	-	-

									Known as Ca half year/ six mo								Amount in	INR Million ex	cept stated otherwise
													dvances or inv	vestments m	ade or given b	able only in case the ro by the listed entity/sul when such transaction	elated party bsidiary. The	transaction re se details nee	
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of	in case ar	ny financials inc nake or give loa				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/ issuance of debt/ any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
231	Zydus Wellness Limited	Mr. Tarun Arora	Key Managerial Personnel	Remuneration		-	N.A.	7	-	-	-		-	-	-	-	-	-	-
232	Zydus Wellness Limited	Mr. Umesh V. Parikh	Key Managerial Personnel	Remuneration		-	N.A.	9	-	-	-		-	-	-	-	-	-	-
233	Zydus Wellness Limited	Mr. Nandish P. Joshi	Key Managerial Personnel	Remuneration	Director	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
234	Zydus Wellness Limited	Ms. Dharmishta N. Raval	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
235	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Interest received		-	N.A.	68	-	-	-	+	-	-		-		-	-
236	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Interest received		-	N.A.	2	-	-	-		-	-	-	-	-	-	-
237	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Loan		-	N.A.	570	-	-	-		-	-	Loan	1M T Bill + 50BPS	1 Year	Unsecured	Business Purpose
238	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Loan		-	N.A.	66	-	-	-		-	-	Loan	6M SOFR + 150BPS	1 Year	Unsecured	Business Purpose
239	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Loan		-	N.A.	200	-	-	-		-	-	-	-	-	-	-
240	Zydus Wellness Limited	Mr. Tarun Arora	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	-	0	-		-	-	-	-	-	-	-
241	Zydus Wellness Limited	Mr. Umesh V. Parikh	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	-	0	-		-	-	-	-	-	-	-
242	Zydus Wellness Limited	Mr. Nandish P. Joshi	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	-	0	-		-	-	-	-	-	-	-
243	Zydus Wellness Limited	Ms. Dharmishta N. Raval	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	0	-	-		-	-	-	-	-	-	-
244	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	2,050	2,463	-		-	-	-	-	-	-	-
245	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.		37	106	-			-	-	-	-	-	
246	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	18	71	-		-	-	-	-	-	-	-
247	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	10	12	-		-	-	-	-	-	-	-
248	Zydus Wellness BD Private Limited	Md Shihab Rizwan	Key Managerial Personnel	Remuneration		-	N.A.	2	-	-	-		-	-	-	-	-	-	-

									Known as Ca half year/ six m								Amount in	INR Million ex	cept stated otherwise
													dvances or in	vestments m	ade or given b	able only in case the r by the listed entity/su when such transaction	elated party bsidiary. Th	transaction re ese details nee	-
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related			In case monie either party a the trans	s a result of		ny financials ind nake or give loa				Details	of loans/ inv	estments	
S. No	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/ issuance of debt/ any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
249	Zydus Wellness International DMCC	Mr. Abhijeet Sahu	Key Managerial Personnel	Remuneration		-	N.A.	11	-	-	-		-	-	-	-	-	-	-
250	Zydus Wellness Products Limited	Zydus Wellness BD Private Limited	Subsidiary Company	Purchase of goods or services		-	N.A.	3	-	-	-	T	-	-	-	-	-	-	-
251	Zudus Wallpass Products	Mukesh M. Patel & Co., Proprietorship Firm	Enterprises significantly	Purchase of goods or		-	N.A.	1	-	-	-		-	-	-	-	-	-	-
252	Zydus Wellness Products Limited	Mr. Tarun Arora	Key Managerial Personnel	Remuneration		-	N.A.	34	-	-	-		-	-	-	-	-	-	-
253	Zydus Wellness Products Limited	Zydus Wellness International DMCC	Subsidiary Company	Sale of goods or services		-	N.A.	35	-	-	-	T	-	-	-	-	-	-	-
254	Zudus Wellness Products	Zydus Healthcare Limited	Subsidiary Company	Sale of goods or services		-	N.A.	74	-	-	-	1	-	-	-	-	-	-	-
255	Zvdus Wellness Products	Zydus Wellness International DMCC	Subsidiary Company	Sale of goods or services		-	N.A.	8	-	-	-	+	-	-	-	-	-	-	-
256	Zydus Wellness Products	Zydus Healthcare Limited	Subsidiary	Sale of goods or		-	N.A.	12	-	-	-		-		-	-	-	-	-
257	Limited Zydus Wellness Products Limited	Zydus Wellness International DMCC	Company Subsidiary Company	services Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	4		-	-			-			-		
258	Zydus Wellness Products Limited	Heinz India Private Limited Provident Fund	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.	12	-	-	-		-	-	-	-	-	-	-
259	Zydus Wellness Products Limited	Heinz India Private Limited Employee Provident Fund	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.	15	-	-	-		-	-	-	-	-	-	-
260	Zydus Wellness Products Limited	Heinz India Private Limited Pension Fund	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.	2	-	-	-		-	-	-	-	-	-	-
261	Zydus Wellness Products Limited	Zydus Wellness Sikkim Employees Group Gratuity Scheme	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.	9	-	-	-		-	-	-	-	-	-	-

									Known as Ca half year/ six m								Amount in	INR Million ex	cept stated otherwise
													dvances or in	vestments m	ade or given b	able only in case the r by the listed entity/su when such transaction	elated party bsidiary. The	transaction re ese details nee	
	Details of the party entering into the transaction	Details of the counte	erparty			Value of the related			In case monie either party a the trans	s a result of		ny financials ind nake or give loa				Details	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/ issuance of debt/ any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
262	Zydus Wellness Products Limited	Zydus Wellness BD Private Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	3	-	-		-	-	-	-	-	-	-
263	Zydus Wellness Products Limited	Zydus Wellness International DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	50	47	-		-	-	-	-	-	-	-
264	Zydus Wellness Products Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	28	23	-		-	-	-	-	-	-	-
265	German Remedies Pharma Private Limited	Mr. Devanand Kumar Singh	Key Managerial Personnel	Remuneration		-	N.A.	9	-	-	-		-	-	-	-	-	-	-
266	German Remedies Pharma Private Limited	Zydus Healthcare Limited	Subsidiary Company	Sale of goods or services		-	N.A.	200	-	-	-	T	-	-	-	-	-	-	-
267	German Remedies Pharma Private Limited	Zydus Lifesciences Limited	Parent Company	Loan		-	N.A.	200	-	-	-		-	-	Loan	TBILL+150 bps	3 Year	Unsecured	Business Purpose
268	German Remedies Pharma Private Limited	Recon Pharmaceuticals and Investments	Subsidiary Company	Any other transaction	Share of profit Received	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
269	German Remedies Pharma Private Limited	Zydus Lifesciences Limited	Parent Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	823	1,035	-		-	-	-	-	-	-	-
270	German Remedies Pharma Private Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	91	24	-		-	-	-	-	-	-	-
271	Zydus Pharmaceuticals Limited	Mr. Vishal Shah	Key Managerial Personnel	Remuneration		-	N.A.	6	-	-	-		-	-	-	-	-	-	-
272	Zydus Pharmaceuticals Limited	Mr. Jignesh Thosani	Key Managerial Personnel	Remuneration		-	N.A.	2	-	-	-		-	-	-	-	-	-	-
273	Zydus Pharmaceuticals Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.	21	-	-	-		-	-	-	-	-	-	-
274	Zydus Pharmaceuticals Limited	Zydus Worldwide DMCC	Subsidiary Company	Sale of goods or services		-	N.A.	172	-	-	-	T	-	-	-	-	-	-	-
275	Zydus Pharmaceuticals Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	-	10	-		-	-	-	-	-	-	-
276	Zydus Pharmaceuticals Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	0		-		-	-	-	-	-	-	-

						•		• •	r Known as Ca half year/ six m			-					Amount in	INR Million ex	cept stated otherwise
													dvances or inv	vestments m	ade or given b	able only in case the ro by the listed entity/sul when such transaction	elated party bsidiary. The	transaction re ese details nee	-
	Details of the party entering into the transaction	Details of the counte	erparty			Value of the related			In case monie either party a the tran	as a result of		ny financials ind nake or give loa				Details o	of loans/ inv	restments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	aparty transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/ issuance of debt/ any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
277	Zydus Animal Health and Investments Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.	4	-	-	-		-	-	-	-	-	-	-
278	Zydus Animal Health and Investments Limited	Zydus Lifesciences Limited	Parent Company	Sale of goods or services		-	N.A.	0	-	-	-		-	-	-	-	-	-	-
279	Zydus Animal Health and	ZyVet Animal Health Inc	Subsidiary	Sale of goods or	·	-	N.A.	285	<u>†</u>	†	-	†	-	-			-	-	
	Investments Limited Zydus Animal Health and		Company Subsidiary	services		+		<b>+</b>	+	+	+	<u> </u>		<u> </u>					
280	Investments Limited Zydus Animal Health and	Viona Pharmaceuticals INC	Company Key	Interest received			N.A.	12				<b> </b>				-			- 
281	Investments Limited	Mr. Pramod Lokhande	Managerial Personnel	Remuneration		-	N.A.	2	-			 		-	-	-	-	-	-
282	Zydus Animal Health and Investments Limited	Mr. Hiren Mistry	Key Managerial Personnel	Remuneration		-	N.A.	1	-	-	-		-	-	-	-	-	-	-
283	Zydus Animal Health and Investments Limited	Mr. Mihir J. Mehta	Key Managerial Personnel	Remuneration		-	N.A.	o	-	-	-		-	-	-	-	-	-	-
284	Zydus Animal Health and Investments Limited	Zydus Lifesciences Limited	Parent Company	Loan		-	N.A.	800	-	-	-		-	-	Loan	TBILL+120 bps	3 Year	Unsecured	Business Purpose
285	Zydus Animal Health and Investments Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	1	1	-		-	-	-	-	-	-	-
286	Zydus Animal Health and Investments Limited	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	411	415	-		-	-	-	-	-	-	-
287	Zydus Animal Health and Investments Limited	ZyVet Animal Health Inc	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	-	191	-		-	-	-	-	-	-	-
288	Zydus Animal Health and Investments Limited	Zydus Lifesciences Limited	Parent Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	-	0	-		-	-	-	-	-	-	-
289	Recon Pharmaceuticals and Investments	Zydus Foundation	Subsidiary Company	Interest received		-	N.A.	1	-	-	-		-	-	-	-	-	-	-
290	Zydus Pharmaceuticals (USA) Inc.	NAI Laboratories Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.	58	-	-	-		-	-	-	-	-	-	-
291	Zydus Pharmaceuticals (USA) Inc.	Navinta III, Inc	Enterprises significantly influenced by Directors and/ or their <u>relatives</u>	Purchase of goods or services			N.A.	65		-	-			-		-	-	-	-
292	Zydus Pharmaceuticals (USA) Inc.	Navinta LLC	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.	98	-	-	-		-	-	-	-	-	-	-

									Known as Ca half year/ six m								Amountin	INP Million or	contistant of home iso
													dvances or in	estments m	ade or given b	able only in case the r by the listed entity/su when such transaction	elated party bsidiary. The	transaction re ese details nee	cept stated otherwise elates to loans, d to be disclosed only
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related			In case monie either party a the trans	s a result of		ny financials ind nake or give loar				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	aparty transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/ issuance of debt/ any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
	Zydus Pharmaceuticals (USA) Inc.	Navinta NV, Inc.	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.	457	-	-	-		-	-	-	-	-	-	-
294	Zydus Pharmaceuticals (USA)	Sentynl Therapeutics Inc.	Subsidiary Company	Sale of goods or services		-	N.A.	3	-	-	-		-	-	-	-	-	-	-
295	Zydus Pharmaceuticals (USA)	Viona Pharmaceuticals INC	Subsidiary	Sale of goods or		<u> </u>	N.A.	2	-			<u>+</u>					<u> </u>	-	
	Inc. Zydus Pharmaceuticals (USA)		Company Subsidiary	services Sale of goods or		<u> </u>	·		<u> </u>			<u> </u>					+	<u>+</u>	
296	Inc.	ZyVet Animal Health Inc	Company Enterprises	services			N.A.	2				<b> </b>	-	-			<u> -</u>		
	Zydus Pharmaceuticals (USA) Inc.	Navinta LLC	significantly influenced by Directors and/ or their relatives	Any other transaction	Reimburseme nt of Expenses paid	-	N.A.	10	-	-	-		-	-	-	-	-	-	-
298	Zydus Pharmaceuticals (USA) Inc.	Nesher Pharmaceuticals (USA) LLC	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	1	-	-	-		-	-	-	-	-	-	-
299	Zydus Pharmaceuticals (USA) Inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	1	-	-	-		-	-	-	-	-	-	-
300	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	3	-	-	-		-	-	-	-	-	-	-
301	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	1	-	-	-		-	-	-	-	-	-	-
302	Zydus Pharmaceuticals (USA) Inc.	Zydus Noveltech Inc.	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
303	Zydus Pharmaceuticals (USA) Inc.	Zynext Ventures USA LLC	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	0	-	-	-	 	-	-	-	-	-	-	-
	Zydus Pharmaceuticals (USA) Inc.	Mahadev Management Inc.	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	5	-	-	-		-	-	-	-	-	-	-
305	Zydus Pharmaceuticals (USA)	Zydus Healthcare (USA) LLC	Subsidiary	Interest received		-	N.A.	6	-	-	-		-	-	-	-	-	-	-
306	Zydus Pharmaceuticals (USA)	Sentynl Therapeutics Inc.	Company Subsidiary	Interest received			N.A.	126	-		<u> </u>	<u>+</u>			 _		<u> </u>	-	
	Inc. Zydus Pharmaceuticals (USA)		Company Subsidiary			<u>+</u>	·	<u> </u>	<u> </u>		+	+	<u> </u>				<u> </u>	<u> </u>	
307	Inc. Zydus Pharmaceuticals (USA)	Viona Pharmaceuticals INC	Company Subsidiary	Interest received			N.A.	15	-	-		<u> </u>	-						-
308	Inc.	ZyVet Animal Health Inc	Company	Interest received			N.A.	10		-		i	-	-	-	-			-
309	Zydus Pharmaceuticals (USA) Inc.	Zydus Therapeutics INC	Subsidiary Company	Interest received			N.A.	76		-	-	<b> </b>	-	-	-	-	-	-	-
310	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Loan		-	N.A.	1	-	-	-	<u> </u>	-	-	Loan	6 M SOFR + 50bps	1 Year	Unsecured	Business Purpose

Zydus Lifesciences Limited [Formerly Known as Cadila Healthcare Limited] Disclosure of related party transactions for the half year/ six months ended September 30, 2023 Amount in INR Million except stated otherwis																	Amountin	INR Million or	cont stated otherwise			
-											Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.											
	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related		Value of	In case monies are due to either party as a result of the transaction			ny financials ind nake or give loan				Details of loans/ investments						
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	transaction as	Remarks on approval by audit committee	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/ issuance of debt/ any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation			
311	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Loan		-	N.A.	107	-	-	-		-	-	Loan	6 M SOFR + 50bps	1 Year	Unsecured	Business Purpose			
312	Zydus Pharmaceuticals (USA)	Zydus Therapeutics INC	Subsidiary Company	Loan		-	N.A.	1,100	-	-	-		-	-	Loan	6 M SOFR + 50bps	1 Year	Unsecured	Business Purpose			
313	Zydus Pharmaceuticals (USA)	Sentynl Therapeutics Inc.	Subsidiary Company	Loan		-	N.A.	660	-	-	-	†	-	-	Loan	6 M SOFR + 50bps	1 Year	Unsecured	Business Purpose			
314	Zydus Pharmaceuticals (USA)	Nesher Pharmaceuticals (USA)	Subsidiary	Loan			N.A.	1	-		-	<b>†</b>	-		Loan	6 M SOFR + 50bps	1 Year	Unsecured	Business Purpose			
315	IRC. Zydus Pharmaceuticals (USA) Inc.	NAI Laboratories Limited	Company Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than Ioans		N.A.	-	-	20	-		-		-		-	-				
316	Zydus Pharmaceuticals (USA) Inc.	Navinta III, Inc	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	-	8	-		-	-	-	-	-	-	-			
317	Zydus Pharmaceuticals (USA) Inc.	Navinta LLC	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	-	28	-		-	-	-	-	-	-	-			
318	Zydus Pharmaceuticals (USA) Inc.	Navinta NV, Inc.	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	-	116	-		-	-	-	-	-	-	-			
319	Zydus Pharmaceuticals (USA) Inc.	Nesher Pharmaceuticals (USA) LLC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	9,326	9,426	-		-	-	-	-	-	-	-			
320	Zydus Pharmaceuticals (USA) Inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	3,990	4,652			-	-	-	-	-	-	-			
321	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	514	520	-		-	-	-	-	-	-	-			
322	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company		Outstanding Receivables - Loans	-	N.A.	-	300	411	-		-	-	-	-	-	-	-			
323	Zydus Pharmaceuticals (USA) Inc.	Zydus Therapeutics INC	Subsidiary Company		Outstanding Receivables - Loans	-	N.A.	-	2,145	3,276	-		-	-	-	-	-	-	-			
324	Zydus Pharmaceuticals (USA) Inc.	Zydus Animal Health and Investments Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	8	-	-		-	-	-	-	-	-	-			
325	Zydus Pharmaceuticals (USA) Inc.	Sentynl Therapeutics Inc.	Subsidiary Company		Outstanding Receivables - Other than loans	-	N.A.	-	2	70	-		-	-	-	-	-	-	-			
326	Zydus Pharmaceuticals (USA) Inc.	Nesher Pharmaceuticals (USA) LLC	Subsidiary Company		Outstanding Receivables - Other than Ioans	-	N.A.	-		0	-		-	-	-	-	-	-	-			

									Known as Ca half year/ six m													
											Amount in INR Million except stated otherwise Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.											
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of		ny financials ind nake or give loa				Details c	f loans/ inv	estments				
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/ issuance of debt/ any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation			
327	Zydus Pharmaceuticals (USA) Inc.	Hercon Pharmaceuticals LLC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	5	-	-		-	-	-	-	-	-	-			
328	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	8	17	-		-	-	-	-	-	-	-			
329	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	15	5	-		-	-	-	-	-	-	-			
330	Zydus Pharmaceuticals (USA) Inc.	Zynext Ventures USA LLC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	-	0	-		-	-	-	-	-	-	-			
331	Zydus Pharmaceuticals (USA) Inc.	Zydus Therapeutics INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	9	16	-		-	-	-	-	-	-	-			
332	Zydus Worldwide DMCC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Purchase of goods or services		-	N.A.	221	-	-	-		-	-	-	-	-	-	-			
333	Zydus Worldwide DMCC	Zydus Pharmaceuticals Limited	Subsidiary Company	Purchase of goods or services		-	N.A.	172	-	-	-		-	-	-	-	-	-	-			
334	Zydus Worldwide DMCC	Zydus Healthcare (USA) LLC	Subsidiary	Purchase of goods or		-	N.A.	8	-	-	-		-	-	-		-	-				
335	Zydus Worldwide DMCC	Mr. Pradeep Agnihotri	Company Key Managerial Personnel	services	Director Sitting Fees and Commission to non executive directors		N.A.	0	-		-			-				-				
336	Zydus Worldwide DMCC	Mr. Ketan Bhut	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	-	1	-		-	-	-	-	-	-	-			
337	Zydus Worldwide DMCC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Sale of goods or services		-	N.A.	6,459	-	-	-		-	-	-	-	-	-	-			
338	Zydus Worldwide DMCC	Viona Pharmaceuticals INC	Subsidiary Company	Sale of goods or services		-	N.A.	37.01	-	-	-	[	-	-	-	-	-	-	-			
339	Zydus Worldwide DMCC	Zydus Netherlands B.V.	Subsidiary Company	Interest received		-	N.A.	15	-	-	-	†	-	-	-	-	-	-				
340	Zydus Worldwide DMCC	Alidac Healthcare (Myanmar) Limited	Subsidiary Company	Interest received		-	N.A.	8	-	-	-	†	-				-	-				
341	Zydus Worldwide DMCC	Zydus Netherlands B.V.	Subsidiary	Loan			N.A.	824	-			†			Loan	6 M SOFR+ 80 BPS	3 Year	Unsecured	Business Purpose			
342	Zydus Worldwide DMCC	Alidac Healthcare (Myanmar)	Company Subsidiary	Loan			N.A.	62	-	-		<u> </u>	-		Loan	6 M SOFR + 75 bps	3 Year	Unsecured	Business Purpose			
	Zydus Worldwide DMCC	Limited Alidac Healthcare (Myanmar) Limited	Company Subsidiary Company	Any other transaction	Outstanding Receivables - Loans		N.A.	-	271	344	-		-	-		-	-	-				
344	Zydus Worldwide DMCC	Zydus Netherlands B.V.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	26	872	-		-	-	-	-	-	-	-			
345	Zydus Worldwide DMCC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	3,328	5,843	-		-	-	-	-	-	-	-			

									Known as Ca half year/ six m								Amount in	INR Million ex	cept stated otherwise			
													dvances or in	vestments n	nade or given b	able only in case the r by the listed entity/su when such transaction	bsidiary. The	ese details nee	elates to loans, ed to be disclosed only			
	Details of the party entering into the transaction	Details of the counte	erparty			Value of the related		Value of	In case monie either party a the trans	is a result of		ny financials ind nake or give loa				Details of loans/ investments						
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/ issuance of debt/ any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation			
346	Zydus Worldwide DMCC	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	3,328	37	-		-	-	-	-	-	-	-			
347	Zydus Therapeutics INC	Mr. Deven Parmar	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	9	15	-		-	-	-	-	-	-	-			
348	Zydus Noveltech Inc.	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Interest received		-	N.A.	5	-	-	-		-	-	-	-	-	-	-			
349	Zydus Noveltech Inc.	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	171	173	-		-	-	-	-	-	-	-			
350	Hercon Pharmaceuticals LLC	Zydus Noveltech Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	335	341	-		-	-	-	-	-	-	-			
351	Zydus Healthcare (USA) LLC	Zydus Worldwide DMCC	Subsidiary Company	Sale of goods or services		-	N.A.	4	-	-	-		-	-	-	-	-	-	-			
352	Zydus Healthcare (USA) LLC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Sale of goods or services		-	N.A.	18.13	-	-	-		-	-	-	-	-	-	-			
353	Zydus Healthcare (USA) LLC	Zydus Therapeutics INC	Subsidiary Company	Sale of goods or services		-	N.A.	3	-	-	-		-	-	-	-	-	-	-			
354	Zydus Healthcare (USA) LLC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	0	-	-	-		-	-	-	-	-	-	-			
355	Zydus Healthcare (USA) LLC	Zydus Therapeutics INC	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	2	-	-	-		-	-	-	-	-	-	-			
356	Zydus Healthcare (USA) LLC	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	4	-	-	-		-	-	-	-	-	-	-			
357	Zydus Healthcare (USA) LLC	Zynext Ventures USA LLC	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	0	-	-	-		-	-	-	-	-	-	-			
358	Zydus Healthcare (USA) LLC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.	-	206	208	-		-	-	-	-	-	-	-			
359	Zydus Healthcare (USA) LLC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	-	0	-		-	-	-	-	-	-	-			
360	Zydus Healthcare (USA) LLC	Zydus Therapeutics INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	1	1	-		-	-	-	-	-	-	-			
361	Zydus Healthcare (USA) LLC	Zynext Ventures USA LLC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	-	0	-		-	-	-	-	-	-	-			
362	Zydus Healthcare (USA) LLC	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	0	8	-		-	-	-	-	-	-	-			

									Known as Ca half year/ six m								Amount in	INR Million ex	cept stated otherwise			
											Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.											
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related			In case monie either party a the trans	s a result of		ny financials ind Nake or give loa				Details of loans/ investments						
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/ issuance of debt/ any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation			
363	ZyVet Animal Health Inc	Zydus Animal Health and Investments Limited	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	42	-	-	-		-	-	-	-	-	-	-			
364	ZyVet Animal Health Inc	Zydus Therapeutics INC	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	0	-	-	-		-	-	-	-	-	-	-			
365	ZyVet Animal Health Inc	Zydus Animal Health and Investments Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	52	-	-				-	-		-	-			
366	Zydus International Private Limited	RIC Chemicals LTD	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.	1	-	-	-		-	-	-	-	-	-	-			
367	Zydus International Private Limited	Mr. Kamlesh K Patel	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	0	-	-	-		-	-	-	-	-	-	-			
368	Zydus International Private Limited	Mr. Govind Hirani	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	0	-	-	-		-	-	-	-	-	-	-			
369	Zydus International Private Limited	Mr. Upen H. Shah	Key Managerial Personnel		Director Sitting Fees and Commission to non executive directors	-	N.A.	0	-	-	-		-	-	-	-	-	-	-			
370	Zydus International Private Limited	Mr. Pradip Solanki	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	0	-	-	-		-	-	-	-	-	-	-			
371	Zydus International Private Limited	Zydus Netherlands B.V.	Subsidiary Company	Interest received		-	N.A.	6	-	-	-	<u> </u>	-	-	-	-	-	-				
372	Zydus International Private Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Interest received		-	N.A.	6	-	-	-		-	-	-	-	-	-	-			
373	Zydus International Private Limited	Zydus France, SAS	Subsidiary Company	Interest received		-	N.A.	7	-	-	-		-	-	-	-	-	-	-			
374	Zydus International Private Limited	Laboratorios Combix S.L.	Subsidiary Company	Interest received		-	N.A.	6	-	-	-		-	-	-	-	-	-	-			
375	Zydus International Private Limited	Zydus Worldwide DMCC	Subsidiary Company	Interest received		-	N.A.	489	-	-	-		-	-	-	-	-	-	-			
376	Zydus International Private Limited	Zydus Netherlands B.V.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	223	226	-		-	-	-	-	-	-	-			
L	L	·	J	·	couns	L		J		L		L	l	L	<b></b> -	L	ll	J	·J			

	Zydus Lifesciences Limited [Formerly Known as Cadila Healthcare Limited] Disclosure of related party transactions for the half year/ six months ended September 30, 2023 Amount in INR Million except stated otherwis															cept stated otherwise						
											Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.											
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related			In case monies are due to either party as a result of the transaction			ny financials ind nake or give loa				Details of loans/ investments						
S. No	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/ issuance of debt/ any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation			
377	Zydus International Private Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	330	331	-		-	-	-	-	-	-	-			
378	Zydus International Private Limited	Zydus France, SAS	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	327	329	-		-	-	-	-	-		-			
379	Zydus International Private Limited	Laboratorios Combix S.L.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	300	302	-		-	-	-	-	-	-	-			
380	Zydus International Private Limited	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	16,034	16,683	-		-	-	-	-	-	-	-			
381	Zydus Netherlands B.V.	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Investment		-	N.A.	826	5,355	6,181	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose			
382	Zydus France, SAS	Sentynl Therapeutics Inc.	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	6	-	-	-		-	-	-	-	-	-	-			
383	Zydus France, SAS	Laboratorios Combix S.L.	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	1	-	-	-		-	-	-	-	-	-	-			
384	Zydus Healthcare S.A. (Pty) Ltd	DI Consultancy	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.	0	-	-	-		-	-	-	-	-	-	-			
385	Zydus Healthcare S.A. (Pty) Ltd	Alidac Pharmaceuticals SA (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	418	397	-		-	-	-	-	-	-	-			
386	Zydus Healthcare S.A. (Pty) Ltd	Alidac Pharmaceuticals SA (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	51	48	-		-	-	-	-	-	-	-			
387	Script Management Services (Pty) Ltd	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Sale of goods or services		-	N.A.	247	-	-	-		-	-	-	-	-	-	-			
388	Script Management Services (Pty) Ltd	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	0	1			-	-		-	-	-	-			
389	Zydus Pharmaceuticals Mexico SA De CV	Alidac Healthcare (Myanmar) Limited	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	68	-	-	-		-	-	-	-	-	-	-			
390	Zydus Healthcare Philippines Inc.	RJ Conception Law Office	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.	0	-	-	-		-	-	-	-	-	-	-			

									Known as Ca alf year/ six mo										
												-					Amount in	INR Million ex	cept stated otherwise
			Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.																
	Details of the party entering into the transaction	Details of the counterparty				Value of the related			In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to				Details of loans/ investments				
S. No	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary		Details of other related party transactions	transaction as	audit	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess [Loans/ issuance of debt/ any other]	Details of other indebtedness	Cost of borrowed funds for the listed entity	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose of the fund utilisation
391		Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	•		-	N.A.	0	-	-	-		-	-	-	-	-	-	-

Notes:

1 Amount mentioned as 0 denotes value less than INR 1 Million.

2 Opening and closing balance are not given where there was no transaction of Investment during the half year ended September 30, 2023.

3 Receivables / Payables other than loans represent combined balance against sales / purchase pertaining to goods/ propoerty, plant and equipment / various services / reimbursement of expenses. Hence shown separately.
 4 Loans given and repaid within reporting period is not disclosed.